Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

In other recent news, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has entered into a significant strategic partnership with Sarepta Therapeutics (NASDAQ:SRPT). The collaboration involves a $500 ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

In other recent news, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has entered into a significant strategic partnership with Sarepta Therapeutics (NASDAQ:SRPT). The collaboration involves a $500 million ...

The revision follows Sarepta's announcement of a major collaboration with Arrowhead Pharmaceuticals (NASDAQ:ARWR) that significantly expands its product pipeline. Sarepta Therapeutics disclosed its ...